What crucial questions demand your attention when completing a Marketing Authorisation Transfer (MAT)?
Regulatory Affairs
We wanted to celebrate our new look website and everyone hopefully having their summer break by now! What better way to celebrate that than with an educational and informative article on the important questions to ask when conducting a Marketing Authorisation Transfer (MAT)? I will guide you through some of the pitfalls in dealing with MAT transfers, whether you are dealing with the divestment of a portfolio or just acquiring a single licence. Happy reading!
https://oriongxp.com/article/what-are-the-top-questions-that-you-need-to-ask-when-completing-an-marketing-authorisation-transfer-mat-
What crucial questions demand your attention when completing a Marketing Authorisation Transfer (MAT)?
These questions are not just routine, but they are the pillars of a successful MAT process. Mergers, Divestments, spin-offs, company splits, or demergers have become more common recently. These deals in the pharmaceutical industry create valuable opportunities for large companies and small biotech operators to collaborate and share resources. This collaboration allows the larger companies to rapidly enhance their research and development pipelines, driving innovation and growth in the industry. For the innovative biotech, there is an exit strategy and recognition for the main players.
